House Dust Mite Extract, from D.farinae

Synonyms: 屋尘螨提取物, 来源粉尘螨
House Dust Mite Extract, from D.farinae 是一种提取自 Dermatophagoides farinae 的屋尘螨过敏原提取物,可显著升高支气管肺泡灌洗液中细胞因子(IL-4、IL-5、IL-6)水平、上调 MUC5AC 过表达,并诱导过敏性哮喘和肺部炎症。
屋尘螨提取物, 来源粉尘螨
产品编号: MS-N00551
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
600μg
询价
3-5 天

产品描述

House Dust Mite Extract, from D.farinae 是一种提取自 Dermatophagoides farinae 的屋尘螨过敏原提取物,可显著升高支气管肺泡灌洗液中细胞因子(IL-4、IL-5、IL-6)水平、上调 MUC5AC 过表达,并诱导过敏性哮喘和肺部炎症。

生物实验数据

生物活性 House Dust Mite Extract, from D.farinae is a house dust mite allergen extract derived from Dermatophagoides farinae that significantly elevates cytokine levels (IL-4, IL-5, IL-6) in bronchoalveolar lavage fluid, upregulates MUC5AC overexpression, and induces allergic asthma and pulmonary inflammation.
IC50 & Target

AAK1

 

IL-6

 

IL-5

 

IL-4

 

体内研究
(In Vivo)

House Dust Mite Extract, from D. farinae (100 μg/mL;经雾化器吸入;8 次;每次 10 分钟) 可在雄性 BALB/c 小鼠中诱导严重的过敏性哮喘病理改变,包括显著的气道高反应性、炎症细胞浸润、Th2 细胞因子产生、免疫球蛋白水平升高、支气管周围纤维化、黏液高分泌以及 MUC5AC 过表达。
House Dust Mite Extract, from D. farinae (3 μg;滴鼻;于第 0、4、7、11、14、18 天给) 可在野生型 C57BL/6 小鼠中诱导强烈的过敏性肺部炎症及 Th2 型适应性免疫应答,而此类应答在 Pla2g5 基因敲除小鼠中显著受损。

Animal Model: BALB/c (5-week-old male; asthma model via nebulization challenge)
Dosage: 100 μg/mL
Administration: inhaled via nebulizer; 8 administrations (Days 7, 14, 21, 28, 35, 42, 60, 61); 10 minutes per administration
Result: Induced airway hyperresponsiveness with significantly higher Penh values than saline-treated control mice (values similar to those induced by D.
pteronyssinus extract).
Significantly increased total cell (~110 × 104/m), eosinophil (~40 × 104/m), neutrophil (~15 × 104/m), lymphocyte (~10 × 104/m), and macrophage (~50 × 104/m) counts in bronchoalveolar lavage fluid compared to saline-treated controls.
Significantly elevated serum IgE (OD ~0.2), IgG1 (OD ~0.15), and IgG2a (OD ~0.12) levels compared to saline-treated controls.
Significantly increased BALF cytokine levels: IL-4 (~150 pg/mL), IL-5 (~150 pg/mL), IL-6 (~40 pg/mL), IL-10 (~75 pg/mL), IL-13 (~150 pg/mL), and IL-17 (~180 pg/mL) compared to saline-treated controls.
Induced pathological lung changes including thickened bronchial mucosa, inflammatory cell infiltration, lumen stenosis, mild peribronchial collagen deposition, increased goblet cell hyperplasia (PAS-positive cell count ~45% of airway cells), and elevated MUC5AC expression (fold change ~8 relative to PBS control for protein, ~8 relative to PBS control for mRNA) compared to saline-treated controls.
Animal Model: C57BL/6 wild-type (WT) (7-9 weeks old); Pla2g5-null (7-9 weeks old)
Dosage: 3 μg
Administration: i.n.; 6 doses on days 0, 4, 7, 11, 14, 18
Result: Induced significant increases in total bronchoalveolar lavage (BAL) fluid cell numbers and eosinophils in WT mice.
Showed 14 bronchovascular bundles (BVBs) with cellular infiltrates per 15 BVBs, and 47 mucus-producing goblet cells per mm of bronchial basal lamina in WT mice.
Increased mRNA expression of IL-5, IL-13, Muc5ac, and Clca3/Gob-5 in lung tissue of WT mice relative to saline controls.
Increased parabronchial lymph node (PLN) cell counts in WT mice, and restimulation of PLN cells with 20 μg/mL D.
farinae induced release of IL-4, IL-5, and IL-13.
Significantly elevated serum levels of D.
farinae-specific IgE, D.
farinae-specific IgG1, and total IgE in WT mice.
Resulted in total BAL fluid cell numbers equivalent to saline controls in Pla2g5-null mice, with significantly reduced total BAL cells and eosinophils compared to D.
farinae-treated WT mice.
Showed 8 BVBs with cellular infiltrates per 15 BVBs, and 10 mucus-producing goblet cells per mm of bronchial basal lamina in Pla2g5-null mice.
Significantly lowered lung mRNA expression of IL-5, IL-13, Muc5ac, and Clca3/Gob-5 in Pla2g5-null mice compared to D.
farinae-treated WT mice.
Significantly reduced PLN cell counts in Pla2g5-null mice compared to D.
farinae-treated WT mice, and restimulated PLN cells released significantly lower levels of IL-4, IL-5, and IL-13.
Dramatically lowered serum levels of D.
farinae-specific IgE, D.
farinae-specific IgG1, and total IgE in Pla2g5-null mice compared to D.
farinae-treated WT mice.
性状 固体
颜色 Light brown to brown

化学信息

别名 屋尘螨提取物, 来源粉尘螨

储存&溶解度

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.

运输条件 Room temperature in continental US; may vary elsewhere.

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础